DrugPatentWatch Database Preview
Sugammadex sodium - Generic Drug Details
What are the generic drug sources for sugammadex sodium and what is the scope of patent protection?
Sugammadex sodium
is the generic ingredient in one branded drug marketed by Organon Sub Merck and is included in one NDA. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.Sugammadex sodium has fifty-six patent family members in thirty countries.
There are two drug master file entries for sugammadex sodium. Two suppliers are listed for this compound.
Summary for sugammadex sodium
| International Patents: | 56 |
| US Patents: | 3 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Drug Master File Entries: | 2 |
| Suppliers / Packagers: | 2 |
| Bulk Api Vendors: | 12 |
| Clinical Trials: | 6 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | sugammadex sodium at DailyMed |
Recent Clinical Trials for sugammadex sodium
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Seoul National University Hospital | Phase 2 |
| Ministry of Food and Drug Safety, Korea | Phase 2 |
| University Health Network, Toronto | Phase 4 |
Pharmacology for sugammadex sodium
Synonyms for sugammadex sodium
| 1202253-72-2 |
| 343306-71-8 |
| 343306-79-6 |
| 361LPM2T56 |
| 862667-16-1 |
| AC-30384 |
| Bridion |
| Bridion (TN) |
| CHEBI:90952 |
| CHEBI:90953 |
| D05940 |
| DB06206 |
| ERJ6X2MXV7 |
| EX-A2600 |
| gamma-Cyclodextrin, 6A,6B,6C,6D,6E,7F,6G,6H-octakis-S-(2-carboxyethyl)-6A,6B,6C,6D,6E,7F,6G,6H-octathio-, octasodium salt |
| MK-8616 |
| Octasodium 6,6',6'',6''',6'''',6''''',6'''''',6'''''''-octakis-S-(2-carboxylatoethyl)-6,6',6'',6''',6'''',6''''',6'''''',6'''''''-octathiocyclo-alpha-(1-4)-D-octaglucopyranoside |
| Org 25969 |
| ORG-25969 |
| SCH-900616 |
| SCHEMBL13917069 |
| Sugammadex |
| Sugammadex [USAN:INN:BAN] |
| Sugammadex sodium (JAN/USAN) |
| Sugammadex sodium [USAN:JAN] |
| UNII-361LPM2T56 |
| UNII-ERJ6X2MXV7 |
Paragraph IV (Patent) Challenges for SUGAMMADEX SODIUM
| Tradename | Dosage | Ingredient | NDA | Submissiondate |
|---|---|---|---|---|
| BRIDION | SOLUTION;INTRAVENOUS | sugammadex sodium | 022225 | 2019-12-16 |
US Patents and Regulatory Information for sugammadex sodium
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Organon Sub Merck | BRIDION | sugammadex sodium | SOLUTION;INTRAVENOUS | 022225-001 | Dec 15, 2015 | RX | Yes | Yes | Start Trial | Start Trial | Y | Y | Start Trial | ||
| Organon Sub Merck | BRIDION | sugammadex sodium | SOLUTION;INTRAVENOUS | 022225-001 | Dec 15, 2015 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Organon Sub Merck | BRIDION | sugammadex sodium | SOLUTION;INTRAVENOUS | 022225-001 | Dec 15, 2015 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Organon Sub Merck | BRIDION | sugammadex sodium | SOLUTION;INTRAVENOUS | 022225-002 | Dec 15, 2015 | RX | Yes | No | Start Trial | Start Trial | Start Trial | ||||
| Organon Sub Merck | BRIDION | sugammadex sodium | SOLUTION;INTRAVENOUS | 022225-002 | Dec 15, 2015 | RX | Yes | No | Start Trial | Start Trial | Start Trial | ||||
| Organon Sub Merck | BRIDION | sugammadex sodium | SOLUTION;INTRAVENOUS | 022225-002 | Dec 15, 2015 | RX | Yes | No | Start Trial | Start Trial | Y | Y | Start Trial | ||
| Organon Sub Merck | BRIDION | sugammadex sodium | SOLUTION;INTRAVENOUS | 022225-002 | Dec 15, 2015 | RX | Yes | No | Start Trial | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for sugammadex sodium
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | 2003515623 | Start Trial |
| Japan | 2003507335 | Start Trial |
| Russian Federation | 2260013 | Start Trial |
| Canada | 2390463 | Start Trial |
| Slovakia | 286282 | Start Trial |
| Australia | 7508900 | Start Trial |
| Czech Republic | 20021814 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for sugammadex sodium
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1259550 | SPC/GB08/057 | United Kingdom | Start Trial | PRODUCT NAME: SUGAMMADEX; REGISTERED: UK EU/1/08/466/001 20080725; UK EU/1/08/466/002 20080725 |
| 1259550 | C01259550/01 | Switzerland | Start Trial | FUSION; FORMER OWNER: ORGANON BIO SCIENCES NEDERLAND B.V., NL |
| 1259550 | 2008C/047 | Belgium | Start Trial | PRODUCT NAME: SUGAMMADEX SODIQUE; AUTHORISATION NUMBER AND DATE: EU/1/08/466001 20080729 |
| 1259550 | 08C0052 | France | Start Trial | PRODUCT NAME: SUGAMMADEX SODIUM; REGISTRATION NO/DATE: EU/1/08/466/001-002 20080725 |
| 1259550 | CA 2009 00002 | Denmark | Start Trial | PRODUCT NAME: SUGAMMADEX ELLER FARMACEUTISK AKTIVE SALTE ELLER ESTERE DERAF, HERUNDER SUGAMMADEXNATRIUM |
| 1259550 | 47/2008 | Austria | Start Trial | PRODUCT NAME: SUGAMMADEX; 6-PER-DEOXY-6-PER-(2-CARBOXYETHYL) THIO-Y-CYCLODEXTRIN UND PHARMAZEUTISCH VERTRAEGLICHES SALZ HIERVON; REGISTRATION NO/DATE: EU/1/08/466/001-002 20080725 |
| 1259550 | SPC031/2008 | Ireland | Start Trial | SPC031/2008: 20090428, EXPIRES: 20230724 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2020 - 2021
NCE-1 Patent Challenge Dates 2020 - 2021
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2020, www.DrugPatentWatch.com.
Follow DrugPatentWatch:
